- Home
- JANX vs PDM Comparison
JANX vs PDM Comparison
Compare JANX & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | PDM |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | JANX | PDM |
|---|---|---|
| Price | $18.33 | $9.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 18 | 4 |
| Target Price | ★ $36.24 | $10.75 |
| AVG Volume (30 Days) | 824.8K | ★ 1.7M |
| Earning Date | 11-05-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,000,000.00 | ★ $564,994,000.00 |
| Revenue This Year | $194.24 | $3.24 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $6.32 |
| 52 Week High | $35.34 | $10.13 |
Technical Indicators
Market Signals| Indicator | JANX | PDM |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 43.04 |
| Support Level | $13.00 | $8.71 |
| Resistance Level | $19.14 | $9.97 |
| Average True Range (ATR) | 0.85 | 0.20 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 81.92 | 38.16 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.